JERSEY CITY, N.J., April 10, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovativeanti-infective therapies for difficult-to-treat and often life-threatening infections, today announced three poster presentations at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April
Title: In Vitro Activity of SCY-078, a Novel IV/Oral Glucan Synthase Inhibitor, against Aspergillus spp., Alone or in Combination with other Antifungal TherapiesPresenter: Mahmoud Ghannoum PhDDate and Time: Saturday, April 21, from 15:30-16:30 CETPoster Presentation #: PO164Session: Aspergillus in the laboratory
Title: Activity of SCY-078 and comparators against a collection of Aspergillus spp. including cryptic species and Cyp51A mutantsPresenter: Ana Alastruey-Izquierdo PhDDate and Time: Saturday, April 21, from 15:30-16:30 CETPoster Presentation #: PO165Session: Aspergillus in the laboratory
Title: SCY-078 Demonstrates Antifungal Activity Against Pneumocystis in a Prophylactic Murine Model of Pneumocystis PneumoniaPresenter: Stephen Barat PhDDate and Time: Sunday, April 22, from 13:30-14:30 CETPoster Presentation #: P1226Session: Update on Pneumocystis
The ECCMID 2018 posters will be available on the SCYNEXIS website following the event.
About SCYNEXISSCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Investor RelationsSusan KimArgot PartnersTel: email@example.com
Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/scynexis-to-present-scy-078-data-at-the-28th-european-congress-of-clinical-microbiology-and-infectious-disease-eccmid-300625304.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All